International Clinical Trial: Cardioprotective Effect of Empagliflozin in Breast Cancer Patients

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815808) titled 'Cardioprotective Effect of Empagliflozin in Breast Cancer Patients' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: Tanta University

Condition: Empgliflozin Cardioprotective Effect

Intervention: Drug: Empagliflozin (EMPA)

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 1, 2026

Target Sample Size: 150

Countries of Recruitment: Egypt

To know more, visit https://clinicaltrials.gov/study/NCT07815808

Published by HT Digital Con...